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Sir: We read with interest the review of Pang et al.
published in the annual review issue of Histopathology
in January 2016, entitled ‘Ductal carcinoma in situ—
update on risk assessment and management’,
wherein a concise overview of the diagnosis and pre-
sent management of ductal carcinoma in situ (DCIS)
is provided, as well as a comprehensive summary of
the histopathological assessment and currently avail-
able prognostic markers.1 We are aware that an
extensive overview of the potential role of the tumour
microenvironment in breast cancer progression was
beyond the scope of this review. Nevertheless, we
would like to draw attention to Figure 1 in the article
of Pang et al., wherein microphotographs of a low-
grade and a high-grade DCIS lesion are shown.1 The
accompanying figure legend points out the differences
between the size and features of the nuclei, but
another remarkable morphological characteristic is
strikingly overlooked: the low-grade lesion is sur-
rounded by a dense sclerotic stroma, whereas the
high-grade lesion is surrounded by an aberrant
stroma that consists of loosely arranged collagen
fibres interspersed with an amorphous, slightly baso-
philic substance.1 We previously described this archi-
tectural change of the periductal stroma in DCIS, and
designated this phenomenon as ‘myxoid’ stroma (Fig-
ure 1).2 In another review on current concepts in
DCIS, a similar omission of periductal stroma is
observed, despite its overt presence in a photograph
of high-grade DCIS.3 Similarly, Shatat et al. did not
comment on the presence of extensive myxoid stroma
in their series of microinvasive carcinomas, whereas
Figure 1 in their article shows a nice illustration of
myxoid periductal stroma in both DCIS and microin-
vasive carcinoma.4
Wernicke et al. were probably the first to describe
myxoid stromal changes in invasive breast cancer,
Figure 1. Microphotographs of two ductal carcinoma in situ (DCIS)
lesions with predominantly sclerotic periductal stroma (A,B) and two
DCIS lesions with predominantly myxoid periductal stroma (C,D).
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and they observed a significant association between the
presence of myxoid stroma and lymph node involve-
ment.5 To our knowledge, no other studies on myxoid
stroma in breast cancer have been reported yet.
We previously observed that myxoid periductal
stroma in DCIS was associated with an increased
overall recurrence risk, and with an increased risk of
invasive recurrence in particular.2 The presence of
myxoid stroma was associated with reduced periduc-
tal decorin expression.2 Although these observations
require validation on larger, independent patient
cohorts, we hypothesize that this myxoid architecture
might mirror an invasion-permissive microenviron-
ment. We speculate that the normal breast stroma
functions as a protective barrier against invasion, and
that its remodelling is likely to enable invasion. Some
preinvasive lesions are able to influence neighbouring
fibroblasts in order to modulate the composition of
their surrounding extracellular matrix.2 Future trans-
lational studies should aim at targeting these adverse
stromal changes, in order to prevent or disrupt the
process of cancer cell invasion.
In summary, we noticed the regular appearance of
several photographs of DCIS with myxoid periductal
stroma in both original reports and review articles,
after we described myxoid stromal changes in DCIS.
In psychology, such a phenomenon is referred to as
‘selective attention bias’ or ‘frequency illusion’, which
is better known as the ‘Baader–Meinhof phenomenon’
in popular literature.6 Remarkably, myxoid stroma is
generally overlooked by authors who publish pho-
tographs of DCIS: myxoid stroma is often overtly pre-
sent, but, as the authors had not yet learned about it,
they did not perceive it. In a certain way, this is a
kind of cognitive bias as well.
We hope that this letter will lead to the acknowl-
edgement of the existence and potential importance
of myxoid stroma in DCIS by other researchers and
experts in this field, including the authors of the
aforementioned articles. Subsequently, this might
stimulate researchers to include assessment of stromal
features in future studies on DCIS, especially in large
ongoing trials such as NSABP B-43, the LORD trial,
and the LORIS trial. If such investigations lead to the
validation of our findings regarding its prognostic
value, myxoid stroma might become part of standard
reporting on DCIS in daily histopathological practice.
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Sir: We thank Van Bockstal et al.1 for their letter,
entitled ‘The Baader–Meinhof phenomenon in ductal
carcinoma in situ of the breast’, in response to our
review ‘Ductal carcinoma in situ—update on risk
assessment and management’.2 Van Bockstal et al.1
raise the issue of the often ignored ductal carcinoma
in situ (DCIS) microenvironment, in particular myx-
oid-appearing stroma, and its role in modulating dis-
ease outcome in DCIS.
As Van Bockstal et al.1 acknowledge, detailed
appraisal of the prognostic significance of the DCIS
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